Sotrovimab in SARS-COV-2 chronic hemodialysis patients in the Omicron era. Is intradialytic administration feasible? Report of 4 cases

Chronic hemodialysis patients are at high risk of morbidity and mortality in case of SARS-CoV-2 infection and they may need to be treated with monoclonal antibodies, either because they have not been vaccinated, or because they have a low anti spike antibody titer. Administration of Sotrovimab has r...

Descripción completa

Detalles Bibliográficos
Autores principales: Mambelli, Emanuele, Gasperoni, Lorenzo, Maldini, Laura, Biagetti, Carlo, Rigotti, Angelo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9469048/
https://www.ncbi.nlm.nih.gov/pubmed/36098880
http://dx.doi.org/10.1007/s40620-022-01449-z
_version_ 1784788551092666368
author Mambelli, Emanuele
Gasperoni, Lorenzo
Maldini, Laura
Biagetti, Carlo
Rigotti, Angelo
author_facet Mambelli, Emanuele
Gasperoni, Lorenzo
Maldini, Laura
Biagetti, Carlo
Rigotti, Angelo
author_sort Mambelli, Emanuele
collection PubMed
description Chronic hemodialysis patients are at high risk of morbidity and mortality in case of SARS-CoV-2 infection and they may need to be treated with monoclonal antibodies, either because they have not been vaccinated, or because they have a low anti spike antibody titer. Administration of Sotrovimab has recently been proposed for hemodialysis patients, but data are on the results lacking. We report on four cases of chronic dialysis patients who received Sotrovimab during intermittent dialysis sessions. In our series, no adverse reactions were recorded; intradialytic administration resulted safe and allowed an adequate observation time without prolonging hospital stay in chronic hemodialysis outpatients.
format Online
Article
Text
id pubmed-9469048
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-94690482022-09-13 Sotrovimab in SARS-COV-2 chronic hemodialysis patients in the Omicron era. Is intradialytic administration feasible? Report of 4 cases Mambelli, Emanuele Gasperoni, Lorenzo Maldini, Laura Biagetti, Carlo Rigotti, Angelo J Nephrol Case Report Chronic hemodialysis patients are at high risk of morbidity and mortality in case of SARS-CoV-2 infection and they may need to be treated with monoclonal antibodies, either because they have not been vaccinated, or because they have a low anti spike antibody titer. Administration of Sotrovimab has recently been proposed for hemodialysis patients, but data are on the results lacking. We report on four cases of chronic dialysis patients who received Sotrovimab during intermittent dialysis sessions. In our series, no adverse reactions were recorded; intradialytic administration resulted safe and allowed an adequate observation time without prolonging hospital stay in chronic hemodialysis outpatients. Springer International Publishing 2022-09-13 2023 /pmc/articles/PMC9469048/ /pubmed/36098880 http://dx.doi.org/10.1007/s40620-022-01449-z Text en © The Author(s) under exclusive licence to Italian Society of Nephrology 2022 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Case Report
Mambelli, Emanuele
Gasperoni, Lorenzo
Maldini, Laura
Biagetti, Carlo
Rigotti, Angelo
Sotrovimab in SARS-COV-2 chronic hemodialysis patients in the Omicron era. Is intradialytic administration feasible? Report of 4 cases
title Sotrovimab in SARS-COV-2 chronic hemodialysis patients in the Omicron era. Is intradialytic administration feasible? Report of 4 cases
title_full Sotrovimab in SARS-COV-2 chronic hemodialysis patients in the Omicron era. Is intradialytic administration feasible? Report of 4 cases
title_fullStr Sotrovimab in SARS-COV-2 chronic hemodialysis patients in the Omicron era. Is intradialytic administration feasible? Report of 4 cases
title_full_unstemmed Sotrovimab in SARS-COV-2 chronic hemodialysis patients in the Omicron era. Is intradialytic administration feasible? Report of 4 cases
title_short Sotrovimab in SARS-COV-2 chronic hemodialysis patients in the Omicron era. Is intradialytic administration feasible? Report of 4 cases
title_sort sotrovimab in sars-cov-2 chronic hemodialysis patients in the omicron era. is intradialytic administration feasible? report of 4 cases
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9469048/
https://www.ncbi.nlm.nih.gov/pubmed/36098880
http://dx.doi.org/10.1007/s40620-022-01449-z
work_keys_str_mv AT mambelliemanuele sotrovimabinsarscov2chronichemodialysispatientsintheomicroneraisintradialyticadministrationfeasiblereportof4cases
AT gasperonilorenzo sotrovimabinsarscov2chronichemodialysispatientsintheomicroneraisintradialyticadministrationfeasiblereportof4cases
AT maldinilaura sotrovimabinsarscov2chronichemodialysispatientsintheomicroneraisintradialyticadministrationfeasiblereportof4cases
AT biagetticarlo sotrovimabinsarscov2chronichemodialysispatientsintheomicroneraisintradialyticadministrationfeasiblereportof4cases
AT rigottiangelo sotrovimabinsarscov2chronichemodialysispatientsintheomicroneraisintradialyticadministrationfeasiblereportof4cases

Ejemplares similares